Location Directory

Clinical trials in Indianapolis, Indiana

This page shows live ClinicalTrials.gov search results for Indianapolis, Indiana, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

8617

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Deep Vein Thrombosis (DVT), Thrombus in the Peripheral Venous Vasculature, Venous Embolism, Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts
Interventions: Aspiration thrombectomy system; Device
Lead sponsor: Argon Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Fort Lauderdale, Florida • Indianapolis, Indiana • Edgewood, Kentucky + 1 more

Conditions: Colitis, Ulcerative
Interventions: Ozanimod; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 36
States / cities: Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 30 more

Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Interventions: Assessment of Therapy Complications, Questionnaire Administration; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 25,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 163
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 124 more

Conditions: Moderate-to-Severe Atopic Dermatitis
Interventions: Nemolizumab; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 1,935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 136
States / cities: Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 104 more

Conditions: Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Interventions: AMG 436; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 7
States / cities: Irvine, California • Newport Beach, California • Zion, Illinois + 4 more

Conditions: Crohn's Disease
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 11
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Oakland, California + 8 more

Conditions: Type 1 Diabetes
Interventions: Denosumab, Placebo; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Duarte, California • Indianapolis, Indiana

Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Interventions: Not listed
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2040
U.S. locations: 136
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 133 more

Conditions: Crohn Disease
Interventions: Anti-TNF therapy; Drug
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 6 Years to 17 Years
Enrollment: 1,270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions: LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 25
States / cities: Duarte, California • Santa Monica, California • Denver, Colorado + 18 more

Conditions: Alopecia Areata
Interventions: Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Brea, California + 39 more

Conditions: Transthyretin Amyloidosis With Cardiomyopathy
Interventions: Nucresiran, Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 45
States / cities: La Jolla, California • Laguna Hills, California • Stanford, California + 38 more

Clinical trials in Indianapolis, Indiana

Filter and sort this location

Live official records

Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Denosumab for Type 1 Diabetes

Product Surveillance Registry

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy